Campomanesia velutina leaves extracts exert hypouricemic effects through inhibition of xanthine oxidase and ameliorate inflammatory response triggered by MSU crystals  by Araújo, Marcela C.P.M. et al.
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Gout  is  a destructive  arthritis  with  a high  prevalence  worldwide.  However,  the  available  therapy  is  not
able  to  increase  life  quality  in  many  patients.  Campomanesia  velutina  (Cambess)  O.  Berg, Myrtaceae,  is
used  in  Brazilian  folk  medicine  to treat pain,  inﬂammation  and  rheumatism.  The  aim  of this  study  was  to
evaluate  the potential  of  ethanolic  and  aqueous  extracts  from  C.  velutina  leaves  to  treat  hyperuricemia
and  inﬂammation  in gout arthritis  model.  Ethanolic  extract  of  leaves  and  aqueous  extract  of leaves  were
in  vitro  assayed  on  xanthine  oxidase  inhibitory  effect  and  in  vivo  on  an experimental  model  of  oxonate-
induced  hyperuricemia  in mice,  liver  xanthine  oxidase  inhibition  and  monosodium  urate  crystal-induced
paw  edema  model.  The  extracts  at both  tested  doses  (100  and  300  mg/kg)  reduced  serum  urate  levels.
They  were  also  able  to inhibit  xanthine  oxidase  in vitro  and  in  vivo,  demonstrating  that  this  might  be  the
mechanism  of  action  underlying  the urate-lowering  effects.  In addition,  the extracts  showed  signiﬁcant
anti-inﬂammatory  activity  on  monosodium  urate  crystal-induced  paw  edema,  especially  aqueous  extract
(100  and  300  mg/kg)  that reduced  edema  at all evaluated  times.  Rutin  and  myricitrin  were  identiﬁed  in
ethanolic  and in  aqueous  extracts.  In this  study,  myricitrin  was  able  to  reduce  serum  uric acid  levels  and
inhibit liver  xanthine  oxidase  at the  dose  of 15 mg/kg.  The  anti-hyperuricemic  activity  of  rutin  has  been
previously  reported.  Thus,  rutin  and  myricitrin  seem  to contribute  to the  observed  effects  of  ethanolic
and  aqueous  extracts.  The  results  demonstrated  the  ability  of  aqueous  and ethanolic  extracts  to  lower
serum  urate  levels  and  to reduce  edema  induced  by monosodium  urate  crystals.  Therefore,  they  may
contribute  to the  management  of  gout  in the  future.
©  2016  Sociedade  Brasileira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  This  is an  open
he CCaccess  article  under  t
ntroduction
Gout is an inﬂammatory disorder that arises when supersatu-
ation of body tissues with urate occurs, leading to the formation
nd deposition of monosodium urate (MSU) crystals in articular
nd periarticular tissues (Roddy and Choi, 2014). The prevalence
f both hyperuricemia and gout has risen in the last decades
nd therefore the burden of gout has increased (Perez-Ruiz et al.,
015). Clinical manifestations of this disease include acute gouty
rthritis ﬂares characterized by severe pain, swelling, warmth and
rythema. If hyperuricemia persists, MSU  crystal deposits further
nduce chronic inﬂammatory responses that may  lead to the for-
ation of tophaceous MSU  crystal deposits in joints and other body
∗ Corresponding author.
E-mail: saude@ef.ufop.br (D.A. Saúde-Guimarães).
http://dx.doi.org/10.1016/j.bjp.2016.05.016
102-695X/© 2016 Sociedade Brasileira de Farmacognosia. Published by Elsevier Edit
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
tissues, chronic joint damage, renal stone formation with potential
renal insufﬁciency and cardiovascular problems (Perez-Ruiz et al.,
2015; Roddy and Choi, 2014).
The therapies for treating gout’s pain and inﬂammation include
nonsteroidal anti-inﬂammatories (NSAID), colchicine and oral
corticosteroids (Edwards and So, 2014). However, MSU  crystal
deposits must be considered the most important target for gout
management. By lowering MSU  levels below 6 mg/dl, dissolution
of pathogenic MSU  crystals is achieved and disappearance of clin-
ical features of gout can be obtained (Perez-Ruiz et al., 2015). The
urate-lowering therapies are based on the use of allopurinol and
probenecid since de 1960s. Recent studies have showed how inad-
equate is the traditional approach to this destructive arthritis. After
all, patients do not experience a signiﬁcant reduction of pain and
intolerance to allopurinol and probenecid means that the patient
would go untreated. These problems have led to the recognition
that gout’s treatment requires better and more speciﬁc agents
(Edwards and So, 2014).
ora Ltda. This is an open access article under the CC BY-NC-ND license (http://
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dark cycle. They were given standard chow and water ad libi-
tum. The experiments with animals were conducted in accordanceM.C. Araújo et al. / Revista Brasileir
Plants have been used for centuries to treat numerous patholog-
cal conditions and diseases and even nowadays, they still provide
 rich source for new drug discoveries due to a tremendous chem-
cal diversity of compounds. Campomanesia species are used in
razilian folk medicine to treat a wide range of clinical conditions,
ncluding their use to treat rheumatism (Alice et al., 1995; Cravo,
994). The term rheumatism includes a wide range of disorders
arked by inﬂammation, degeneration and pain, affecting con-
ective tissues structures, specially joints and related structures
Dorland’s Medical Dictionary, 2007). The specie Campomanesia
elutina (Cambess) O. Berg, Myrtaceae, can be found in the Brazilian
errado bioma and there are reports about its use by the popula-
ion of its occurrence area (Dias and Laureano, 2009; Giraldi and
anazaki, 2010; Oliveira et al., 2010). Previous studies with this
pecie assessed its anti-inﬂammatory and antinociceptive activities
n vivo and lead to the isolation of the active constituent myricitrin
rom the ethanolic extract of leaves (Michel et al., 2013).
Since Campomanesia species are used to treat rheumatism
nd previous studies demonstrated the anti-edematogenic and
ntinociceptive activity of the specie, this study was conducted in
rder to evaluate the role of C. velutina in gout, a known and preva-
ent rheumatic disease. Thus, the aim of this study is to evaluate the
iological effects of aqueous and ethanolic extracts from C. velutina
eaves over the hyperuricemia and inﬂammation triggered by MSU
rystals. The ability of extracts to inhibit xanthine oxidase (XO) was
lso evaluated both in vitro and in vivo. In addition, it was  evalu-
ted myricitrin ability to inhibit XO and thus reduce uric acid levels
n vivo.
aterials and methods
hemicals
Xanthine oxidase from cow’s milk, xanthine, potassium oxonate,
ric acid, allopurinol and indomethacin were purchased from
igma–Aldrich (USA). Uric acid assay kit was purchased from Bio-
lin (Brazil). Ketamine and xylazine were obtained from Sespro
ndustria e Comercio Ltda (Brazil). Water was puriﬁed using Milli-
 apparatus from Millipore (USA). Ethanol, dimethylsulphoxide
DMSO) and Tween 80 were of analytical grade. HPLC solvents were
urchased from Tedia (Brazil) and standards were purchased from
igma–Aldrich (USA).
lant material
Leaves from Campomanesia velutina (Cambess.) O. Berg, Myr-
aceae, were collected in Lagoa Santa city, Minas Gerais state, Brazil,
n December of 2012, with permission of Chico Mendes Institute of
iodiversity Conservation (Instituto Chico Mendes de Conservac¸ ão
a Biodiversidade – ICMBio/Sistema de Autorizac¸ ão e Informac¸ ão
m Biodiversidade – SISBIO), license no. 17021-5. The plant botan-
cal identiﬁcation was realized by Dr. Marcos E. Guerra Sobral from
he Department of Natural Sciences, Federal University of São João
el-Rei (Universidade Federal de São João Del-Rei (UFSJ), Minas
erais, Brazil. A voucher specimen (HUFSJ 4637) was deposited at
he herbarium of UFSJ.
reparation of plant extracts
The leaves were air-dried and powdered. Part of the leaves
owder (540 g) was exhaustively extracted with ethanol at room
emperature by percolation. Solvent was removed under reduced
ressure, at 40 ◦C, yielding 41 g of the dried ethanolic extract of
eaves (EEL). In order to obtain the aqueous extracts, 450 g of leaves
owder was percolated with 4.5 l of water. The water was  removedarmacognosia 26 (2016) 720–727 721
by lyophilization, yielding 19 g of the aqueous extract of leaves
(AEL).
Characterization of the extracts by HPLC-UV/DAD
HPLC-UV/DAD analysis were performed on a Waters Liquid
Chromatography (model Alliance 2695) equipped with a vacuum
degasser, a quaternary pump, an auto sampler, a diode array detec-
tor (DAD Waters 2996) and reversed phase C18 column (Shimadzu
ODS – 250 mm × 4.6 mm,  5 m).
To assign compounds to the peaks, it was  used the retention
time and UVmax of standards eluted on the same conditions as the
extracts. The following standards were used: oleanolic acid, chloro-
genic acid, caffeic acid, galocatequin, quercetin, pinocembrin, rutin,
kaempferol, crisin and myricitrin. To obtain the HPLC proﬁles, the
UV-DAD detector was  set to record between 200 and 400 nm and
UV chromatograms were recorded at 254 nm.
The extracts and the standards were solubilized in methanol to
yield a concentration of 5 mg/ml  and 1 mg/ml, respectively. Then,
they were ﬁltered through a 0.45 m Millex syringe ﬁlters. The
volume injected was 25 l. EEL was  eluted in a system with 5%
of methanol and 95% of water, taking 60 min  to reach 100% of
methanol and another 5 min to return to the initial condition. The
ﬂow rate was kept constant at 1 ml/min. AEL was eluted in a sys-
tem with 100% of water, taking 30 min  to reach 20% of methanol,
another 10 min  to reach 40% of methanol and 15 min to reach 100%
of methanol. The system was returned to the initial condition in
5 min. The ﬂow rate was kept constant at 0.8 ml/min. In both cases,
the separation temperature was 25 ◦C.
Inhibition of XO activity in vitro
To evaluate the effect of the extracts over XO activity, it was
used the method described by Ferraz-Filha et al. (2006) with
modiﬁcations. The EEL was  dissolved in DMSO:Tween 80:Water
(1:1:8) and the AEL was dissolved in water. The assay mixture
consisted of 500 l of extract solution, 1125 l of 1/15 M phosphate
buffer (pH 7.5) and 187.5 l of enzyme solution (0.28 units/ml
in buffer). The reaction was initiated by adding 1375 l of xan-
thine substrate solution (0.15 mM in water). The assay mixture
was incubated at 25 ◦C and the absorbance (295 nm) was mea-
sured spectrophotometrically every minute for 12 min  using a Cary
50 Bio Spectrophotometer (Varian – Australia). A blank (0% of XO
inhibition) was  prepared without the extracts solutions. Allopu-
rinol was  used as a positive control. XO inhibitory activity was
expressed as the percentage of XO inhibition in the assay mixture
system and calculated as: % inhibition = (1 − test inclination/blank
inclination) × 100, where test inclination is the linear change in
absorbance of test material per minute and blank inclination is the
linear change in absorbance of blank per minute. To calculate IC50,
ﬁnal concentrations of extracts were 10, 20, 30, 40 and 50 g/ml
and ﬁnal concentrations of allopurinol were 0.1, 0.25, 0.5, 0.75 and
1 g/ml. All assays were performed in triplicate.
Animals
Animal Science Center of Universidade Federal de Ouro Preto
supplied the male albino Swiss mice (25–30 g) for the experi-
ments. Animals were divided into experimental groups (n = 6 or
n = 9), housed in plastic cages and maintained on a 12-h light/12-hwith the Guide for the Care and Use of Laboratory Animals of the
National Institute of Health (NIH). The Ethical Committee on Animal
Experimentation of UFOP (no. 2012/69) approved all experimental
procedures.
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reparation of drugs and test solutions
Allopurinol, indomethacin, myricitrin, Campomanesia velutina
xtracts and potassium oxonate were prepared according to the
verage weight of each experimental group. Potassium oxonate
250 mg/kg) and MSU  crystals (80 mg/ml) were suspended in
.9% sterile saline. Allopurinol (10 mg/kg), indomethacin (3 mg/kg)
nd EEL (100 and 300 mg/kg) were solubilized in DMSO:Tween
0:water (1:1:8). AEL (100 and 300 mg/kg) was solubilized in water
nd myricitrin (15 mg/kg) was solubilized in DMSO:water (5:95).
ll solutions and suspensions were prepared on the day of their
se.
nti-hyperuricemic effects and inhibition of liver XO residual
ctivity in oxonate-induced hyperuricemic mice
The anti-hyperuricemic activity of myricitrin, AEL and EEL was
valuated using an experimental animal model of hyperuricemia
nduced by potassium oxonate, an uricase inhibitor, as previously
escribed by Hall et al. (1990) and modiﬁed by others (de Souza
t al., 2012; Lemos et al., 2015). Animals were divided into exper-
mental groups (n = 6) and fasted 1 h before drug administration.
otassium oxonate was administrated intraperitoneally to animals
n the ﬁrst and third day of the experiment 1 h before oral admin-
stration of test solutions. Mice of normal control group were not
reated with potassium oxonate. All treatments were orally admin-
stered by gavage once a day for three consecutive days. Mice of
ormal control and hyperuricemic control groups received only
ehicle (DMSO:Tween 80:water or DMSO:Water). Animals from
reated control group received allopurinol. Animals of remaining
roups were treated with myricitrin, EEL and AEL. On the third day,
 h after the last oral test administration, mice were anesthetized
ith a mixture of ketamine and xylasine (100 and 20 mg/kg, respec-
ively) and the blood was collected through cardiac puncture. The
lood was allowed to clot for approximately 45 min  at room tem-
erature and then centrifuged at 3500 × g for 10 min. Sera were
eparated and stored at −20 ◦C until assay for uric acid quantiﬁca-
ion. The liver was removed, washed in 0.9% saline and stored at
80 ◦C.
ric acid assay
Serum uric acid concentration was spectrophotometrically
Varian Cary 50 Bio Spectrophotometer, Australia) determined by
nzymatic colorimetric method (UOD-PAP) using a standard diag-
ostic kit (Bioclin, Brazil) according to manufacturer’s instructions.
his test is based on uric acid oxidation by uricase producing allan-
oin and hydrogen peroxide which is used by peroxidase to produce
 red chromogen through the reaction of 4-aminoantipyrine with
he hydroxyl-dichloro-benzene sulphonic acid (HDBS). The color
ntensity is proportional to the concentration of uric acid in the
ample with maximum absorption at 505 nm.
iver XO activity assay
Enzyme extraction from liver was carried out according to pre-
iously described (Zhu et al., 2004; Haidari et al., 2008). Liver
O residual activity was assayed spectrophotometrically by mon-
toring uric acid formation from xanthine according to method
escribed by Hall et al. (1990) and modiﬁed by others (de Souza
t al., 2012; Ferrari et al., 2016). Brieﬂy, 100 l of livers ﬁnal super-
atant were pre-incubated for 15 min  at 37 ◦C with 5000 l of
0 mM phosphate buffer (pH 7.4) containing 1 mM of potassium
xonate. The presence of potassium oxonate prevents the oxida-
ion of uric acid to allantoin. Then, the reaction was  initiated by
he addition of 1200 l of 250 mM xanthine solution. The addi-
ion of 500 l of 0.6 M HCl solution to the reaction medium afterarmacognosia 26 (2016) 720–727
0 and 30 min  stopped the reaction. The reaction mixtures were
then centrifuged at 3000 × g for 5 min. The supernatants were sep-
arated and the absorbance measured at 295 nm (Varian Cary 50 Bio
Spectrophotometer, Australia). The amount of uric acid formed was
quantiﬁed by the difference of absorbance from 30 and 0 min  using
a uric acid calibration curve. XO residual activity was  expressed
as nanomoles of uric acid formed per minute per milligram of
protein. Protein concentration was determined spectrophotomet-
rically using method described by Bradford (1976).
Monosodium urate crystal-induced inﬂammation in mice
The anti-inﬂammatory activity of Campomanesia velutina leaves
extracts was evaluated on an experimental model of gout accord-
ing to previously described by (Rassol and Varalakshimi, 2006) and
modiﬁed by others (de Souza et al., 2012; Lemos et al., 2015; Ferrari
et al., 2016). Animals were divided into seven experimental groups
(n = 9) and fasted 1 h before drug administration. Inﬂammation was
induced on the ﬁrst day of the experiment by intradermal injec-
tion of 50 l of MSU  crystal suspension into the mice right hind
paw. MSU  crystals were prepared according to previously described
method (Rassol and Varalakshimi, 2006). All animals received MSU
injection, except those from normal control group (group 1), which
were administered only saline. All treatments were orally admin-
istered by gavage 1 h before MSU  injection on the ﬁrst day and
repeated daily, at the same time, for three more days. Animals from
group 1 and 2 were treated with the vehicle and served as normal
control group and MSU-induced control group, respectively. Mice
of group 3 were treated with the standard anti-inﬂammatory drug
indomethacin. Animals of remaining groups (4–7) were treated
with EEL and AEL (100 and 300 mg/kg). Paw thickness was mea-
sured with a caliper rule (150 mm–6  in., Vonder, China) before and
4, 24, 48 and 72 h after MSU  injection. Inﬂammatory swelling was
expressed as percentage of thickness variation.
Statistical analysis
Experimental data was  analyzed using GraphPad Prism 5.0 Soft-
ware (Inc., San Diego, CA, USA). IC50 values were calculated by
linear regression of plots on an XY graph of inhibition versus con-
centration values, assuming a 95% conﬁdence interval. Results
from in vivo experiments were presented as mean values ± S.E.M.
One-way analysis of variance (ANOVA) was used followed by
Newman–Keuls’ multiple comparison test. p values < 0.05 were
considered statistically signiﬁcant.
Results and discussion
Brazilian traditional medicine uses Campomanesia species to
treat pain, inﬂammation and rheumatism. Rheumatism is a generic
term used to describe various clinical conditions that affect mus-
cles, bones or articulations causing reduction or loss of mobility, as
arthritis, gout, arthrosis, among others.
Gout is one of the most common metabolic diseases and
affects thousands of people worldwide. Hyperuricemia charac-
terizes gout and leads to the deposit of MSU  crystals in joints,
resulting in a marked local inﬂammatory process with progres-
sive loss of function (Roddy and Choi, 2014). Recent data have
shown that hyperuricemia and gout are increasing worldwide.
Such an epidemic has deleterious consequences on not only joint
function, health resources utilization, and quality of life, but may
also increase cardiovascular mortality. Therefore, reducing MSU
levels is the main strategy to treat gout and implementation of
anti-inﬂammatory prophylaxis prior to or at the initiation of urate-
lowering therapy to prevent the occurrence of ﬂares is highly
recommended (Perez-Ruiz et al., 2015). Thus, anti-inﬂammatory
and anti-hyperuricemic properties are convenient for compounds
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ntended to treat gout (Ahmad et al., 2008), and in this context,
atural products are a potential source of new agents (Kong et al.,
002).
Previous studies with Campomanesia velutina demonstrated
hat the specie possess antinociceptive and anti-inﬂammatory
roperties (Michel et al., 2013). The aim of this study was  to eval-
ate the ability of the specie to lower serum urate levels and
nvestigate the mechanisms underlying this effect. In addition, was
nvestigated its ability to act over the inﬂammatory process trig-
ered by MSU  crystals. This way, the results obtained may  help
evelop an alternative therapy to treat gout, since the traditional
pproach to this disease has low efﬁcacy and various side effects
nd restrictions.
Flavonoids are naturally occurring plant compounds with
ntioxidant, anti-inﬂammatory and XO inhibitory properties
Nagao et al., 1999; Tung et al., 2015). Furthermore, their con-
umption has been associated with the protective effects of certain
iets and herbs against some of the complications of hyperuricemia
nd gout, such as cardiovascular disease and diabetes (Sampson
t al., 2002). A study also demonstrated the ability of the ﬂavonoid
uercetin to prevent kidney injury associated with hyperuricemia
Wang et al., 2012). As ﬂavonoids possess important biological
ffects in inﬂammation and hyperuricemia, HPLC analysis was car-
ied out in order to verify the presence of some common ﬂavonoids
nd correlated phenolic substances. AEL and EEL proﬁle showed
t retention time of approximately 43 and 30 min, respectively,
he presence of substances that absorb energy at two different
avelengths, like ﬂavonoids. The extraction of the chromatograms
t 254 nm and the comparison of retention time and UVmax of
he peaks with standards revealed the presence of two  distinct
avonoids at those retention times (Fig. 1). The presence of the
avonoid myricitrin was conﬁrmed in EEL and found in AEL. In
ddition, another ﬂavonoid, rutin, was found in EEL and AEL.
Myricitrin and rutin have been reported to possess a wide range
f biological activities and many of these activities are related to
he biological effects investigated in this study. In previous studies,
yricetin-3-O-rhamnoside (myricitrin) was able to modulate the
elease and/or production of NO, TNF- and IL-10 on macrophagestracted UV spectrum of identiﬁed and standards substances myricitrin and rutin.
(Ferreira et al., 2013; Michel et al., 2013). In vivo, myricitrin has
been reported as a nitric oxide (NO) and protein kinase C inhibitor
that exerts antinociceptive effect (Meotti et al., 2006) and its oral
administration reduced TNF- and COX-2 expression in mice livers
(Domitrovic´ et al., 2015). Myricitrin also showed inhibitory effects
against TNF- production in RAW264.7 macrophages (Shimosaki
et al., 2011) and irreversibly inactivated myeloperoxidase activity,
closely related to the progression of chronic inﬂammatory diseases
(Meotti et al., 2011).
Rutin is a typical ﬂavonoid with several biological effects
demonstrated in vitro and in vivo including antioxidative, anti-
inﬂammatory, anticancer, antidiabetic, antimicrobial, antifungal,
anti-allergic, among others. Most of these activities are attributed
to the potent antioxidant property of rutin, particularly as a free
radical scavenger (Chua, 2013). Rutin can inhibit XOD in vitro (Chen
et al., 2011) and a three-day oral pretreatment with rutin produced
a dose-dependent decrease on serum urate levels in hyperuricemic
mice and these effects were partly due to inhibition of XDH/XO
activities in mouse liver (Zhu et al., 2004). Rutin also have the abil-
ity to inhibit NO production induced by LPS (Shen et al., 2002) and
the anti-inﬂammatory activity of rutin was  found to be beneﬁcial
for the treatment of rheumatoid arthritis and osteoarthritis (Umar
et al., 2012).
XO is the enzyme responsible for the conversion of hypoxan-
thine into xanthine and of xanthine into uric acid. Assays with
this enzyme are used to test compounds that may  inhibit the
enzyme and thus be useful to the treatment of gout and others
diseases related to XO (Haidari et al., 2008). Two different extracts
obtained from Campomanesia velutina leaves (EEL and AEL) were
assayed for XO inhibitory activity in vitro. The results are shown
in Table 1. At ﬁnal concentration of 100 g/ml, the two extracts
produced an inhibition greater than 60% over XO. The IC50 values
were determined for both of them since the extracts presented an
inhibition bigger than 25% at 100 g/ml. EEL showed an IC50 value
of 35.63 g/ml. For AEL, the IC50 was  47.33 g/ml. Allopurinol IC50
was 0.3287 g/ml. According to Schmeda-Hirschmann et al. (1996),
compounds with IC50 values lower than 50 g/ml should be further
investigated. Thus, both extracts were in vivo assayed to verify if
724 M.C. Araújo et al. / Revista Brasileira de Farmacognosia 26 (2016) 720–727
Table 1
Xanthine oxidase inhibitory activity of ethanolic and aqueous extracts from Campo-
manesia velutina leaves.
Extract Inhibition at 100 g/ml
(% ± S.E.M.)
IC50 g/ml
(Conﬁdence interval – 95%)
EEL 66.43 ± 3.17 35.63 (30.14 to 42.84)
AEL 66.82 ± 1.19 47.33 (45.06 to 49.89)
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Table 2
Effects of ethanolic and aqueous extracts from Campomanesia velutina leaves on liver
xanthine oxidase residual activity after a three-day oral administration.
Treatment Dose (mg/kg) XOD (nm/min/mg protein) % Inhibition
Vehicle – 14.86 ± 0.802 –
Allopurinol 10 4.21 ± 0.429a 71.67
EEL 100 7.76 ± 1.452a 47.78
300 7.49 ± 0.496a 49.59
AEL 100 5.89 ± 0.569a 60.36
300 5.28 ± 0.345a 64.47
EEL, ethanolic extract of leaves; AEL, aqueous extract of leaves; nm,  nanomoles of
uric acid.
both extracts. In fact, myricitrin and rutin were found in AEL and
EEL. Previous studies with rutin demonstrated the ability of this
ﬂavonoid to decrease serum urate levels in hyperuricemic mice
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he activity observed in vitro would produce important biological
ffects.
In most mammals, uricase is an enzyme that catalyses the con-
ersion of uric acid into allantoin, thus, serum uric acid levels is
ypically low. However, human and other primates lost the ability
o express uricase and the result is higher serum uric acid levels.
otassium oxonate is the most used uricase inhibitor in animal
odels of hyperuricemia, since it is a low-cost compound and
roduces a rapid effect. Therefore, the hyperuricemic model pro-
uced by oxonate is the most suitable to the preliminary study
f new drugs (Kong et al., 2002). Thus, to assay the hypouricemic
ctivity of Campomanesia velutina, hyperuricemic oxonate-induced
nimals were treated for three days with EEL and AEL at 100 and
00 mg/kg. Fig. 2 shows the results.
Treatment with uricase inhibitor potassium oxonate signiﬁ-
antly increased serum urate levels when compared to normal
roup, showing that the model was effective to induce hyper-
ricemia. A three-day treatment with the two extracts, at both
oses (100 and 300 mg/kg) signiﬁcantly reduced serum urate levels
ompared to hyperuricemic control group. As observed on in vitro
ssays, extracts were also able to inhibit XO residual activity in vivo.
s shown in Table 2, treatment with EEL and AEL for three days
as able to inhibit liver XO residual activity in hyperuricemic mice
t both doses when compared to control group. Since the reduc-
ion of serum uric acid levels was followed by XO inhibition, these
esults indicate that the anti-hyperuricemic activity of the extracts
s strongly related to XO inhibition and this might be the mecha-
ism of action.
Statistical analysis revealed that there were no differences
etween the doses concerning uric acid levels and XO inhibition,
his is probably because the maximum response was reached with
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ig. 2. Anti-hyperuricemic effects of ethanolic and aqueous extracts from Campo-
anesia velutina leaves in mice treated with potassium oxonate. Data represents
eans ± S.E.M. of six animals. One-way ANOVA followed by Newman–Keuls’ multi-
le comparison test was used for statistical signiﬁcance. ***p < 0.001 compared with
yperuricemic control group. ###p < 0.001 compared with normal control group.Data represents mean ± S.E.M. of six animals. One-way ANOVA followed by
Newman–Keuls’ multiple comparison test was used for statistical signiﬁcance.
a p < 0.001 compared to hyperuricemic control group.
the dose of 100 mg/kg. This way, an increase in the dose did not
produce a better response. In addition, results of uric acid and XO
inhibition exhibited no statistical differences between AEL and EEL.
This probably means that the active compounds are present onXO residual ctivity
***
***
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Fig. 3. Myricitrin effects over serum uric acid levels and XO residual activity in
mice treated with potassium oxonate. Data represents means ± S.E.M. of six animals.
One-way ANOVA followed by Newman–Keuls’ multiple comparison test was used
for  statistical signiﬁcance. ***p < 0.001 compared with hyperuricemic control group.
##p  < 0.01 and ###p < 0.001 compared with normal control group.
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ine  animals. One-way ANOVA followed by Newman–Keuls’ multiple comparison te
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ith a three-day oral pretreatment (Zhu et al., 2004) and to inhibit
O in vivo (Zhu et al., 2004) and in vitro (Chen et al., 2011). Because
he lack of studies about the anti-hyperuricemic activity of myric-
trin, this ﬂavonoid was further investigated and the results showed
hat myricitrin was able to signiﬁcantly reduce serum uric acid lev-
ls and to inhibit XO residual activity after a three-day treatment
t the dose of 15 mg/kg (Fig. 3). Thus, it is reasonable to assume
hat myricitrin and rutin are related to the effects of AEL and EEL
ver serum uric acid levels and XO residual activity. However, other
ompounds can also contribute to the observed effect, since the full
omposition of the extracts is not known.
Furthermore, the results of uric acid levels and XO inhibition
rom animals treated with the extracts were not signiﬁcantly dif-
erent of those observed on normal group. Allopurinol (10 mg/kg)
educed serum urate levels of hyperuricemic mice to values lower
han that found in normal group (Fig. 2) and inhibited 71.67% of
O activity (Table 2). However, the fact that the extracts did not
roduce such reduction can be considered an advantage. Despite
levated serum uric acid levels can trigger gout and other metabolic
isorders, the antioxidant activity of uric acid, particularly its ability
o inhibit DNA damage, is well documented (Stinefelt et al., 2005).
herefore, an excessive decrease in uric acid levels may  even be
armful (Haidari et al., 2008). Thus, as the extracts reduced serum
rate to the same levels observed in normal animals, a possible
herapy with them could lead to fewer side effects.
Previous studies with EEL demonstrated its ability to inhibit
dema formation after a carrageenan injection (Michel et al., 2013).
owever, there were no data concerning the aqueous extract or
he role of the specie over a gout-like inﬂammation. Therefore, AEL
nd EEL were tested about their ability to prevent edema forma-
ion triggered by MSU  crystals. MSU  crystal injection starts a local
nﬂammatory reaction with symptoms similar to those observed
linically in gout, suggesting that this model is able to predict
linical efﬁcacy of new agents (Getting et al., 2002). MSU  crys-
als stimulate innate immune system through the production andna on MSU  crystal-induced paw edema in mice. Data represents means ± S.E.M. of
s  used for statistical signiﬁcance. *p < 0.05, *p < 0.01 and ***p < 0.001 compared with
release of several inﬂammatory mediators, such as kinins, inter-
leukins and TNF-. Some of these mediators are chemotactics and
amplify the inﬂammatory response leading to neutrophil inﬁltra-
tion followed by the release of oxygen free radicals, lysosomal
enzymes, prostaglandin-E2, leukotrienes and interleukin-1.  If not
treated, the inﬂammation can lead to structural damage (Martinon
et al., 2006).
MSU  crystals injection caused a signiﬁcant increase in paw
thickness when compared to negative control (saline administra-
tion). Indomethacin (3 mg/kg) promoted a signiﬁcant reduction
on paw swelling observed during the entire experiment. The two
extracts at both doses reduced edema formation at 4th hour after
MSU  injection, but only AEL (100 and 300 mg/kg) was able to main-
tain the activity throughout the experiment. EEL limited only initial
inﬂammatory response, evaluated 4 h after MSU-crystal injection
(Fig. 4). These results indicate that EEL acts only on the initial phase
of the inﬂammatory process initiated by MSU  crystals while AEL can
act both in the initial and in the late phases of the inﬂammatory pro-
cess. Myricitrin and rutin can be involved in the anti-inﬂammatory
activity of the extracts too. As previously detailed, several studies
demonstrated the ability of these ﬂavonoids to inhibit the produc-
tion and/or the release of inﬂammatory mediators.
The prevalence of gout and hyperuricemia are increasing and
the deleterious outcomes of these diseases demonstrate the neces-
sity to treat properly those patients. Gout usual treatment includes
the use of anti-inﬂammatory drugs for symptom relief, especially
pain, and the use of XO inhibitors or uricosuric agents to reduce
serum uric acid. The problem with this approach is the numerous
side effects, the poor control of pain and the high cost. Therefore, the
use of a unique agent to treat inﬂammation, pain and hyperuricemia
would be the ideal scenario of gout treatment (Yao et al., 2012). The
results of this study are very promising, since the extracts were able
to inhibit XO and thus reduce serum uric acid levels. Furthermore,
the extracts were able to inhibit edema formation after MSU crystal
injection, indicating a potential anti-inﬂammatory activity. It is also
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alid to point out that these effects were observed at the same doses
nd after an oral treatment, indicating that the active substances
re well absorbed in the intestinal tract. This way, aqueous and
thanolic extracts from Campomanesia velutina leaves can act over
rucial points of gout management: decrease uric acid serum lev-
ls by inhibiting xanthine oxidase activity and reduce paw edema
nduced by MSU. Therefore, these extracts are a promising alter-
ative to treat gout and could be used for the development of an
erbal medicine or as a source of new molecules to treat this dele-
erious disease and thus contribute to increase the armamentarium
o achieve a properly management of gout and a good life quality
or those patients. However, more studies are necessary to establish
ll the substances in the extracts that are responsible for the activ-
ty, identify and propose the molecular mechanisms under these
ffects.
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